🇺🇸 FDA
Patent

US 10493087

Sialylation-increasing therapies for diseases associated with oxidative stress

granted A61KA61K31/7008A61K31/7012

Quick answer

US patent 10493087 (Sialylation-increasing therapies for diseases associated with oxidative stress) held by The United States of America, as represented by National Institute of Health expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by National Institute of Health
Grant date
Tue Dec 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/7008, A61K31/7012, A61K31/702, A61K31/7088